Publications

Pour rechercher une publication scientifique, insérez vos mots-clés en anglais.

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues.

Abstract

The medical humanitarian organization Médecins Sans Frontières (MSF) provides medical care in more than 70 countries and admits more than 7000 cases of snakebite in its facilities each year.

Julien Potet Saschveen Singh Koert Ritmeijer Kasaye Sisay Gabriel Alcoba Fabienne Jouberton et al.
Toxicon: X. Volume 17, March 2023, 100146. Published online 2022 Dec 21. doi: 10.1016/j.toxcx.2022.100146
snakebite Antivenoms

Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial.

Abstract

BACKGROUND: Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or antibiotic failure.

Marcy O Wobudeya E Font H Vessière A Chabala C Khosa C Taguebue JV Moh R Mwanga-Amumpaire J Lounnas M Mulenga V Mavale S Chilundo J Rego D Nduna B Shankalala P Chirwa U De Lauzanne A Dim B Tiogouo Ngouana E Folquet Amorrissani M Cisse L Amon Tanoh Dick F Komena EA Kwedi Nolna S Businge G Natukunda N Cumbe S Mbekeka P Kim A Kheang C Pol S Maleche-Obimbo E Seddon JA Mao TE Graham SM Delacourt C Borand L Bonnet M
The Lancet. Infectious diseases 2022 Nov 14; . doi: 10.1016/S1473-3099(22)00668-5. Epub 2022 11 14

Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion.

Abstract

BACKGROUND: Conversion of sputum culture from positive to negative for M. tuberculosis is a key indicator of treatment response. An initial positive culture is a pre-requisite to observe conversion.

Rodriguez CA Lodi S Horsburgh CR Bastard M Hewison C Huerga H Khan M Khan PY Khan U Oyewusi L Padayachee S Mitnick CD Franke MF
PloS one 2022 ; 17(11); . doi: 10.1371/journal.pone.0276457. Epub 2022 11 10

Differential symptomology of possible and confirmed Ebola virus disease infection in the Democratic Republic of the Congo: a retrospective cohort study.

Abstract

BACKGROUND: In its earliest phases, Ebola virus disease's rapid-onset, high fever, and gastrointestinal symptoms are largely indistinguishable from other infectious illnesses.

Nsio J Ardiet DL Coulborn RM Grellety E Albela M Grandesso F Kitenge R Ngwanga DL Matady B Manangama G Mossoko M Ngwama JK Mbala P Luquero F Porten K Ahuka-Mundeke S
The Lancet. Infectious diseases 2022 Nov 09; . doi: 10.1016/S1473-3099(22)00584-9. Epub 2022 11 09

Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial.

Abstract

BACKGROUND: Tuberculous meningitis (TBM) is the most lethal and disabling form of tuberculosis (TB), particularly in sub-Saharan Africa.

Maitre T Bonnet M Calmy A Raberahona M Rakotoarivelo RA Rakotosamimanana N Ambrosioni J Miró JM Debeaudrap P Muzoora C Davis A Meintjes G Wasserman S Wilkinson R Eholié S Nogbou FE Calvo-Cortes MC Chazallon C Machault V Anglaret X Bonnet F
Trials 2022 Nov 08; 23(1); . doi: 10.1186/s13063-022-06772-1. Epub 2022 11 08
Aspirin HIV, High-dose rifampicin Linezolid Randomized controlled trial Tuberculous meningitis
Hodson DZ Mbarga Etoundi Y Mbatou Nghokeng N Mohamadou Poulibe R Magne Djoko S Goodwin J Cheteug Nguesta G Nganso T Armstrong JN Andrews JJ Zhang E Wade M Eboumbou Moukoko CE Boum Y Parikh S
Malaria journal 2022 Oct 22; 21(1); . doi: 10.1186/s12936-022-04315-2. Epub 2022 10 22
Anaemia Cameroon Douala Febrile illness Malaria Plasmodium falciparum Urban

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.

Abstract

BACKGROUND: ERVEBO®, a live recombinant vesicular stomatitis virus (VSV) vaccine containing the Zaire ebolavirus glycoprotein (GP) in place of the VSV GP (rVSVΔG-ZEBOV-GP), was advanced through clinical development by Merck & Co.,

Simon JK Kennedy SB Mahon BE Dubey SA Grant-Klein RJ Liu K Hartzel J Coller BG Welebob C Hanson ME Grais RF
Vaccine 2022 Oct 05; . doi: 10.1016/j.vaccine.2022.09.037. Epub 2022 10 05
Ebola Immunogenicity Vaccine

Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines.

Abstract

OBJECTIVES: To evaluate the cost-effectiveness of alternative rotavirus vaccines in Niger, using UNIVAC, a proportionate outcomes model.

Debellut F Tang K Clark A Pecenka C Assao B Guindo O Grais RF Isanaka S
BMJ open 2022 Oct 05; 12(10); . doi: 10.1136/bmjopen-2022-061673. Epub 2022 10 05
Health economics Health policy Paediatric infectious disease & immunisation Public health

TB screening, prevention and treatment cascade in a Malawi prison.

Abstract

Incarcerated individuals, especially in high HIV and TB burden settings, are at increased risk of latent TB infection and/or TB disease. We implemented a comprehensive HIV-TB intervention in a Malawi prison and studied its feasibility.

Mangochi P Bossard C Catacutan C Van Laeken D Kwitonda C Ortuno R Chiwaula L Meis M Abura A Furin J Mpunga J Goemare E Ellman T Garone D Ferlazzo G Isaakidis P
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2022 Oct 01; 26(10); . doi: 10.5588/ijtld.22.0115. Epub 2022 09 28